Статья
ХРОНИЧЕСКАЯ ОБСТРУКТИВНАЯ БОЛЕЗНЬ ЛЕГКИХ КАК ФАКТОР РИСКА РАЗВИТИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ
Тесная взаимосвязь между сердечно-сосудистыми заболеваниями (ССЗ) и хронической обструктивной болезнью легких (ХОБЛ) привлекает к себе внимание в течение последних лет как один из аспектов системных проявлений ХОБЛ. Высокая распространенность ССЗ у больных ХОБЛ объясняется концепцией персистирующего системного низкоинтенсивного воспаления. В настоящем обзоре ХОБЛ рассматривается с позиции фактора риска развития ССЗ, что требует соответствующего мультидисциплинарных диагностического и лечебного подходов.
1. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 2009; 4: 337-49.
2. Sidney SM, Sorel CP, Quesenberry JR, et al. COPD and incident cardiovascular disease hospitalizations and mortality: kaiser permanente medical careprogram. Chest 2005; 128(4): 2068-75.
3. Cui H, Miao D-M, Wei Z-M, et al. Prevalence of cardiovascular disease in subjects hospitalized due to chronic obstructive pulmonary disease in Beijing from 2000 to 2010. J Geriatr Cardiol 2012; 9(1): 5-10.
4. Macchia A, Moncalvo R JJ, Kleinert M, et al. Unrecognized ventricular dysfunction in COPD. Eur Respir J 2012; 39(1): 51-8.
5. Bursi F, Vassallo R, Weston SA, et al. Chronic obstructive pulmonary disease after myocardial infarction in the community. Am Heart J 2010; 160(1): 95-101.
6. Hawkins NM, Huang Z, Pieper KS. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the valsartan in acute myocardial infarction trial (VALIANT). Eur J Heart Fail 2009; 3: 292-8.
7. Angouras DC, Anagnostopoulos CE, Chamogeorgakis TP, et al. Postoperative and long-term outcome of patients with chronic obstructive pulmonary disease undergoing coronary artery bypass grafting. Ann Thorac Surg 2010; 4: 1112-8.
8. Ford ES, Wheaton AG, Mannino DM, et al. Elevated cardiovascular risk among adults with obstructive and restrictive airway functioning in the United States: a cross-sectional study of the National Health and Nutrition Examination Survey from 2007–2010. Respiratory Research 2012; 13: article 115.
9. Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67(11): 957-63.
10. Cao C, Wang R, Wang J, et al. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS ONE 2012; 7: 1-8.
11. Man SFP, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 10: 849-53.
12. McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH clinical endpoint committee. Thorax 2007; 62(5): 411-5.
13. Brekke PH, Omland TP, Smith S, et al. Under diagnosis of myocardial infarction in COPD—Cardiac Infarction Injury Score (CIIS) in patients hospitalized for COPD exacerbation. Respir Med 2008; 102(9): 1243-7.
14. Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009; 136(2): 376-80.
15. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 2008; 29(1): 96-103.
16. Corrales-Medina F, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010; 10(2): 83-92.
17. Huiart L, Ernst P, Ranouil X, et al. Oral corticosteroid use and the risk of acute myocardial infarction in chronic obstructive pulmonary disease. Can Respir J 2006; 13(3): 134-8.
18. Warren-Gash C, Smeeth L, Hayward AC. Inflenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis 2009; 9(10): 601-10.
19. Soteriades ES, Smith DL, Tsismenakis AJ, et al. Cardiovascular disease in US firefighters: a systematic review. Cardiol Rev 2011; 19(4): 202-15.
20. Man SFP, van Eeden S, Sin DD. Vascular risk in chronic obstructive pulmonary disease: role of inflammation and other mediators. Can J Cardiology 2012; 6: 653-61.
21. Theofilogiannakos EK, Anogeianaki A, Tsekoura P, et al. Arrhythmogenesis in patients with stable chronic obstructive pulmonary disease. J Cardiovascr Med 2008; 9(1): 89-93.
22. Malysh EY, Ovsynnikov ES, Semynina NM, et al. State of the autonomic nervous system in patients with chronic obstructive pulmonary disease and hypertension. Vrach-aspirant 2014; 2.1(63): 186-91. Russian (Малыш Е.Ю., Овсянников Е.С., Семынина Н.М. и др. Состояние вегетативной нервной системы у больных хронической обструктивной болезнью легких и артериальной гипертензией. Врач-аспирант 2014; 2.1(63): 186-91).
23. Corbo GM, Inchingolo R, Sgueglia GA, et al. C-reactive protein, lung hyperinflation and heart rate variability in chronic obstructive pulmonary disease—a pilot study. COPD 2013; 10: 200-7.
24. Chhabra L, Sareen P, Perli D, et al. Vertical P-wave axis: the electrocardiographic synonym for pulmonary emphysema and its severity. Indian Heart J 2012; 64(1): 40-2.
25. Warnier MJ, Rutten FH, Numans ME, et al. Electrocardiographic characteristics of patients with chronic obstructive pulmonary disease. COPD 2013; 10(1): 62-71.
26. Warnier MJ, Rutten FH, Anthonius de B, et al. Resting Heart Rate Is a Risk Factor for Mortality in Chronic Obstructive Pulmonary Disease, but Not for Exacerbations or Pneumonia. PLoS One 2014; 9(8): e105152. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144884/
27. Vanfleteren LE, Franssen FM, Uszko-Lencer NH, et al. Frequency and relevance of ischemic electrocardiographic findings in patients with chronic obstructive pulmonary disease. Am J Cardiol 2011; 108(11):1669-74.
28. Bhatt SP, Nanda S, Kintzer JS. Arrhythmias as trigger for acute exacerbations of chronic obstructive pulmonary disease. Respir Med 2012;106:1134-8.
29. Caglar IM, Dasli T, Caglar TFN, et al. Evaluation of atrial conduction features with tissue doppler imaging in patients with chronic obstructive pulmonary disease. Clinical Research in Cardiology 2012; 101(8): 599-606.
30. McCullough PA, Neyou A. Comprehensive Review of the Relative Clinical Utility of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide Assays in Cardiovascular Disease. Open Heart Failure J 2009; 2: 6-17.
31. Mueller C, Laule-Kilian K, Frana B, et al. Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. Am Heart J 2006; 151(2): 471-7.
32. Budnevsky AV, Ovsjannikov ES, Chernov AV. Prognostic value of biomarkers in assessing the effectiveness of treatment of chronic obstructive pulmonary disease (review of the literature). Molodoj uchenyj 2014; 65(6): 284-7. Russian (Будневский А.В., Овсянников Е. С., Чернов А.В. Прогностическое значение биомаркеров в оценке эффективности терапии хронической обструктивной болезни легких (обзор литературы). Молодой ученый 2014; 65(6): 284-7).
33. Tribuntseva LV, Budnevsky AV. System analysis of the effectiveness of treatment of chronic obstructive pulmonary disease in general practice (family medicine). Vestnik novykh meditsinskikh tekhnologiy 2013; 1. http:// www.medtsu.tula.ru/VNMT/Bulletin/E2013-1/4536.pdf Russian (Трибунцева Л.В., Будневский А.В. Системный анализ эффективности терапии хронической обструктивной болезни легких в общей врачебной практике (семейной медицине). Вестник новых медицинских технологий 2013; 1. http:// www.medtsu.tula.ru/VNMT/Bulletin/E2013-1/4536.pdf).
34. Abroug F, Ouanes-Besbes L, Nciri N, et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006; 174(9): 990-6.
35. Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011; 66(9): 764-8.
36. Rutten FH, Cramer M-J M, Zuithof N PA, et al. Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail 2007; 9(6-7): 651-9.
37. Hoiseth AD, Neukam A, Karlsson D, et al. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax 2011; 66: 775-81.
38. Brekke PH, Omland T, Holmdel SH, et al. Determinants of cardiac troponin T elevation in COPD exacerbation — a cross-sectional study. BMC Pulmonary Medicine 2009; 9(1): art.35.
39. Corrales-Medina VF, Serpa J, Rueda AM, et al. Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore) 2009; 88: 154-9.
40. Anthonisen NR, Connett JE, Enright PL, et al. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-9.
41. Van Eeden SF, Sin DD. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008; 75: 224-38.
42. Malysh EY, Drobysheva ES, Chernov AV. Chronic obstructive pulmonary disease and damage of the cardiovascular system. Molodoj uchenyj 2014; 64(5): 145-8. Russian (Малыш Е.Ю., Дробышева Е. С., Чернов А.В. Хроническая обструктивная болезнь легких и поражение сердечно-сосудистой системы. Молодой ученый 2014; 64(5): 145-8).
43. Miyata R, Hiraiwa K, Cheng JC, et al. Statins reduce ambient particulate matterinduced lung inflammation by promoting the clearance of particulate matter from lung tissues. Chest 2013; 143(2): 452-60.
44. The effect of statins in patients with chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/NCT01151306